-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 19, Shanghai Modern Pharmaceutical issued an announcement stating that its wholly-owned subsidiary Sinopharm Jinshi received the Cefprozil Dry Suspension (0.
125g) "Drug Supplementary Application Approval Notice" approved and issued by the State Drug Administration, and approved the The drug passed the consistency evaluation of generic drugs
.
Cefprozil is a long-acting, broad-spectrum second-generation cephalosporin antibiotic.
It is generally used clinically to treat infectious diseases caused by sensitive bacteria, including upper respiratory tract infections, lower respiratory tract infections, and skin and soft tissue infections
.
The drug was first developed by Bristol-MyersSquibb in the United States, and was first marketed in the United States in 1991
According to data from the PDB Drug Comprehensive Database, global sales of cefprozil dry suspension in 2020 will be 117.
2 million U.
S.
dollars; domestic sample hospital sales will be 130.
9 million yuan
.
According to the CDE website, Nanjing Yihua Pharmaceutical Co.
, Ltd.
and Hainan Rizhongtian Pharmaceutical Co.
, Ltd.
also have passed the consistency evaluation of cefprozil dry suspension (0.
125g)
.
Sinopharm Jinshi used to carry out the consistency evaluation of cefprozil dry suspension (0.